Completed PHASE4 INTERVENTIONAL 1-arm NCT01420055

Fingolimod -Response According to Coping - Evaluation (GRACE)

A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France

Sponsor: Novartis Pharmaceuticals

Conditions Multiple Sclerosis, Relapsing-Remitting

Interventions fingolimod

Updated 6 times since 2017 Last updated: Nov 16, 2016 Started: Aug 31, 2011 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01420055, this PHASE4 trial focuses on Multiple Sclerosis, Relapsing-Remitting and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Agen, France , Amiens, France , Angers, France , Auxerre, France , Avignon, France , Bayonne, France , Bobigny, France , Brest, France , Béziers, France , Calais, France and 35 more locations